Boston Scientific (NYSE:BSX) Updates FY 2026 Earnings Guidance

Boston Scientific (NYSE:BSX) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 3.280-3.320 for the period, compared to the consensus estimate of 3.360. The company issued revenue guidance of $21.2 billion-$21.4 billion, compared to the consensus revenue estimate of $21.6 billion. Boston Scientific also updated its Q3 2026 guidance to 0.800-0.820 EPS.

Analysts Set New Price Targets

A number of brokerages recently issued reports on BSX. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $60.00 target price on shares of Boston Scientific in a research report on Thursday. Mizuho lowered their price target on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. Citigroup dropped their price target on shares of Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research report on Thursday. Zacks Research downgraded shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Finally, Needham & Company LLC decreased their price objective on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a report on Wednesday, July 8th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Price Performance

NYSE:BSX opened at $45.92 on Friday. The firm has a market cap of $68.25 billion, a P/E ratio of 18.59, a PEG ratio of 0.89 and a beta of 0.58. Boston Scientific has a 52-week low of $42.20 and a 52-week high of $109.50. The business’s 50-day moving average price is $46.35 and its 200 day moving average price is $62.37. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.36% and a net margin of 17.50%.The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the company posted $0.75 EPS. Boston Scientific’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts predict that Boston Scientific will post 3.31 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has approved a share buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Insider Activity

In other news, Director Edward J. Ludwig acquired 3,580 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the purchase, the director owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director David C. Habiger acquired 2,250 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the transaction, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. This trade represents a 19.35% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought a total of 9,800 shares of company stock valued at $554,012 over the last 90 days. 0.34% of the stock is currently owned by company insiders.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded second-quarter expectations, reporting adjusted EPS of $0.86 versus $0.83 expected and revenue of $5.44 billion versus approximately $5.38 billion expected. Revenue increased 7.5% year over year, supported by broad-based cardiovascular growth, international sales and margin expansion. Boston Scientific Q2 Earnings & Revenues Top Estimates
• Positive Sentiment: Management raised its full-year sales-growth outlook to roughly 5.5%–6.5%, while highlighting cost savings, new product launches and a multiyear restructuring plan intended to improve efficiency. The planned restructuring could ultimately generate about $500 million in savings. Boston Scientific Q2 Results, Recall and Restructuring Plan
• Positive Sentiment: Boston Scientific’s pending acquisition of Penumbra adds exposure to thrombectomy and embolization markets. Penumbra reported second-quarter revenue of $390.0 million, up 14.9% year over year, with gross margin improving to 67.9%. Penumbra Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Despite lower targets, UBS, BTIG, TD Cowen and Truist maintained buy ratings. Their revised targets—$74, $60, $56 and $57, respectively—still imply substantial upside, but the reductions signal more cautious near-term expectations. BTIG Lowers Boston Scientific Price Target
• Negative Sentiment: Boston Scientific cut full-year adjusted EPS guidance to $3.28–$3.32 from $3.34–$3.41, below the roughly $3.31 consensus midpoint, and set third-quarter EPS guidance at $0.80–$0.82. Softer demand for the WATCHMAN heart-implant portfolio and pressure in electrophysiology were the primary concerns. Boston Scientific Lowers Full-Year Guidance
• Negative Sentiment: The company also disclosed a recall involving its Rapid Refill Continuous Injection System and restructuring costs of up to $800 million. These charges weigh on earnings visibility even though management expects longer-term operating benefits. Boston Scientific Cuts Outlook Ahead of Restructuring

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Morgan Stanley boosted its stake in Boston Scientific by 10.8% in the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock valued at $2,189,289,000 after buying an additional 2,246,308 shares in the last quarter. Northern Trust Corp grew its position in Boston Scientific by 0.9% during the 3rd quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider’s stock worth $1,406,129,000 after acquiring an additional 128,188 shares during the last quarter. Amundi raised its position in Boston Scientific by 3.6% in the 4th quarter. Amundi now owns 12,415,159 shares of the medical equipment provider’s stock valued at $1,183,785,000 after purchasing an additional 433,575 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Boston Scientific by 30.7% during the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock worth $956,680,000 after purchasing an additional 2,301,383 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Boston Scientific by 1.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 8,946,503 shares of the medical equipment provider’s stock valued at $853,049,000 after buying an additional 104,190 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.